老虎證券
Invest
Pricing
Rewards
Support
About
Quotes
TigerAI
登入
立即註冊
Toggle
澳股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
MESOBLAST LTD
2.060
-0.060
-2.83%
成交量:
255.90萬
成交額:
531.95萬
市值:
26.72億
市盈率:
-33.06
高:
2.140
開:
2.110
低:
2.060
收:
2.120
52周最高:
3.310
52周最低:
1.880
股本:
12.97億
流通股本:
7.86億
量比:
1.32
換手率:
0.33%
股息:
- -
股息率:
- -
每股收益(TTM):
-0.062
每股收益(LYR):
-0.062
淨資產收益率:
-9.86%
總資產收益率:
-4.11%
市淨率:
3.35
市盈率(LYR):
-33.06
資料載入中...
總覽
公司
新聞資訊
公告
概念
新冠治療股
+0.93%
醫藥生物股
+1.18%
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
Mesoblast Limited:預計短期內將持續面臨重大虧損
美股速递
·
08/27
Mesoblast完成慢性腰痛關鍵性3期試驗患者治療,達成重大里程碑
美股速递
·
08/17
Mesoblast報告Ryoncil®季度淨營收3600萬美元,產品上市首年淨營收達1.15億美元
美股速递
·
07/30
Mesoblast首席執行官增持股份以強化股權
投资观察
·
07/21
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/MSB.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.06,"timestamp":1789452720000,"preClose":2.12,"halted":0,"volume":2559013,"delay":0,"changeRate":-0.028301886792452855,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1296862776,"eps":-0.062306520012461314,"marketStatus":"未開盤","change":-0.06,"latestTime":"09-15 16:12:00 AEST","open":2.11,"high":2.14,"low":2.06,"amount":5319531,"amplitude":0.037736,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.062306520012461314,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":2.12,"openAndCloseTimeList":[[1789430400000,1789452000000]],"volumeRatio":1.3197131445789778,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":2.06,"auctionPrice":2.07,"auctionVolume":27467,"auctionTime":1789516275725,"referenceTime":1789468203091,"auction":1,"marketStatus":"盘前竞价","timestamp":1789516275725}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-4.11%","roe":"-9.86%","lyrEps":-0.062307,"volumeRatio":1.3197131445789778,"shares":1296862776,"dividePrice":0,"high":2.14,"amplitude":0.037736,"preClose":2.12,"low":2.06,"week52Low":1.88,"pbRate":"3.35","psRate":"15.83","week52High":3.31,"institutionHeld":0,"latestPrice":2.06,"eps":-0.062306520012461314,"divideRate":0,"volume":2559013,"delay":0,"ttmEps":-0.062306520012461314,"open":2.11,"prevYearClose":2.72,"prevWeekClose":2.15,"prevMonthClose":2.36,"prevQuarterClose":1.955,"fiveDayClose":2.29,"twentyDayClose":2.4,"sixtyDayClose":2.17,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787702400000,"name":null,"time":"","dateTimestamp":1787666400000,"actualEps":null},{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1198020721","title":"Mesoblast Limited:預計短期內將持續面臨重大虧損","url":"https://stock-news.laohu8.com/highlight/detail?id=1198020721","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198020721?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 06:27","pubTimestamp":1787783223,"startTime":"0","endTime":"0","summary":"Mesoblast Limited近日发出预警,表明公司可能在未来可预见的一段时期内,继续承受显著的财务亏损。Mesoblast在研发上的持续投入,虽然从长远来看可能带来丰厚回报,但短期内却不可避免地加重了其财务负担。在当前生物科技板块波动加剧的背景下,Mesoblast的这一声明或将引发市场对其未来融资策略和现金流状况的更多关注。Mesoblast能否在亏损泥潭中找到突破口,市场正拭目以待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK7067","MSB.AU","BK7501","MESO","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176396021","title":"Mesoblast完成慢性腰痛關鍵性3期試驗患者治療,達成重大里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1176396021","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176396021?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 08:36","pubTimestamp":1786926968,"startTime":"0","endTime":"0","summary":"Mesoblast(MESOBLAST LTD)在治疗慢性腰痛的关键性3期临床试验中,已顺利完成全部患者的治疗工作。这一成就标志着该公司在推进这一潜在疗法上迈出了决定性的一步。临床试验的完成,不仅为后续的数据分析铺平了道路,也极大地提振了市场对这款创新疗法的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7501","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134208248","title":"Mesoblast報告Ryoncil®季度淨營收3600萬美元,產品上市首年淨營收達1.15億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134208248","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134208248?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 08:59","pubTimestamp":1785373168,"startTime":"0","endTime":"0","summary":"Mesoblast(股票代码:MSB.AU)公布了其核心产品Ryoncil®的财务表现。数据显示,该公司在最近一个季度录得净营收3600万美元(约合3600万美元)。不仅如此,从产品正式上市至今的第一个完整财年内,Ryoncil®累计贡献的净营收总额已达到1.15亿美元。这一成绩标志着该产品在商业化初期便展现出强劲的市场接纳度与增长潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","BK7501","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157804936","title":"Mesoblast首席執行官增持股份以強化股權","url":"https://stock-news.laohu8.com/highlight/detail?id=1157804936","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157804936?lang=zh_tw&edition=fundamental","pubTime":"2026-07-21 09:53","pubTimestamp":1784598831,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd宣布,其首席执行官已通过投资进一步增持公司股份。具体而言,该首席执行官行使了190万份股票期权,行权价为每股1.45澳元,总价值达273万澳元。此次交易后,其持股总数增加至8080万股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","MSB.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/MSB.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"新冠治療股","id":"package_au_concept_xgzlg","bkCode":"BK7501","changeRate":0.00931},{"market":"AU","name":"醫藥生物股","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":0.011805}]}}